Millicent Manufacturing Pr Patent-Cliff Exposure & CMS Drug Spending Portfolio

Millicent Manufacturing Pr (US): 2 reconciled FDA prescription therapies, $8.0M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2041-01-01
2024 CMS Total Public Spend$8.0M
2024 Medicare Part D Spend$7.0M
2024 Medicaid Spend$982K
California HCAI SB 17 Filings8 WAC filings (max 31.1% 2-yr change)